Schering AG licenses SEGRA compound for ophthalmic use to
Bausch & Lomb
Berlin, Germany, and Rochester, New York, USA, September 18, 2006 -
Schering AG, Germany (FSE: SCH; NYSE: SHR) and Bausch & Lomb (NYSE: BOL)
announced today that Schering has granted an exclusive worldwide license to
Bausch & Lomb to develop and market a selective glucocorticoid receptor
agonist (SEGRA) for the non-systemic treatment of eye disorders.

Bausch & Lomb will evaluate the compound's potential as a novel anti-
inflammatory medication with an improved safety profile in ophthalmological
indications. Today, glucocorticoids are the most potent and most frequently
used anti-inflammatory compounds, but their value is limited by side
effects such as glaucoma induction. SEGRAs, using a distinct molecular
mechanism after binding to a glucocorticoid receptor, may demonstrate a
superior effect/side effect profile when compared to standard
glucocorticoids.

"The collaboration with Bausch & Lomb is an excellent opportunity for us to
broadly explore the potential of SEGRAs and capitalize on the full value of
these compounds," said Dr. Khusru Asadullah, Head of Inflammation Research
at Schering AG.

"Our agreement with Schering, a pre-eminent name in the development and
commercialization of pharmaceuticals, is yet another example of how we at
Bausch & Lomb are actively pursuing unique compounds and creative
therapeutic approaches in order to expand our pipeline of new products to
help people with vision-threatening ophthalmic conditions," said Praveen
Tyle, Ph.D., Bausch & Lomb Chief Scientific Officer and Senior Vice
President ? Global Research and Development. "We believe that the SEGRA
technology is a natural fit with Bausch & Lomb's ocular anti-inflammatory
expertise, and would strategically complement our portfolio of proprietary
loteprednol-based anti-inflammatory products, Lotemax(r), Alrex(r)
and Zylet(r)."

Under the terms of the agreement, Bausch & Lomb is responsible for
development of the SEGRA compound for non-systemic use in ophthalmology.
Bausch & Lomb will make upfront and milestone payments based on the
development and registration progress, and pay ongoing royalties based on
product sales. Further details of the agreement were not disclosed.

About Schering AG
Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic
Imaging as well as Specialized Therapeutics for disabling diseases. As a
global player with innovative products, Schering AG aims for leading
positions in specialized markets worldwide. With in-house R&D and supported
by an excellent global network of external partners, Schering AG is
securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve
the quality of life: making medicine work

It is planned that Schering AG will be renamed Bayer Schering Pharma
Aktiengesellschaft. A corresponding resolution was passed at the
Extraordinary General Meeting of Schering AG on September 13, 2006. Until
the name change has been registered in the commercial register, the company
will continue to operate under the name Schering AG. According to the
resolution of the General Meeting, the Executive Board will not file an
application for registration before December 1, 2006.

Find additional information at: www.schering.de/eng

About Bausch & Lomb
Bausch & Lomb is the eye health company, dedicated to perfecting vision and
enhancing life for consumers around the world. Its core businesses include
soft and rigid gas permeable contact lenses and lens care products, and
ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is
one of the best known and most respected healthcare brands in the world.
Founded in 1853, the Company is headquartered in Rochester, New York.
Bausch & Lomb's 2004 revenues were $2.2 billion; it employs approximately
13,700 people worldwide and its products are available in more than 100
countries. More information about the Company can be found on the Bausch &
Lomb Web site at www.bausch.com.


This press release has been published by Corporate Communication of
Schering AG, Berlin, Germany.

Your contacts at Schering AG:
Media Relations: Oliver Renner , T: +49-30-468 124 31,
oliver.renner@schering.de
Investor Relations: Peter Vogt, T: +49-30-468 128 38,
peter.vogt@schering.de

Your contacts at Bausch & Lomb:
Media Relations: Margaret Graham, T.: +1-585-338-5469, MGraham@bausch.com
Investor Relations: Daniel L. Ritz, T.: +1-585-338-5802, DRitz@bausch.com